• Sleep-wake disorders

Lumryz Generic Name & Formulations

General Description

Sodium oxybate 4.5g, 6g, 7.5g, 9g; pkts for ext-rel oral susp.

Pharmacological Class

Antinarcoleptic (CNS depressant).

How Supplied

Pkts—7, 30


Generic Availability


Mechanism of Action

Sodium oxybate is the sodium salt of gamma-hydroxybutyrate (GHB), an endogenous compound and metabolite of the neurotransmitter GABA. It is hypothesized that its therapeutic effects  on cataplexy and excessive daytime sleepiness are mediated through GABAB actions at noradrenergic and dopaminergic neurons, as well as at thalamocortical neurons.

Lumryz Indications


Cataplexy or excessive daytime sleepiness in adults with narcolepsy.

Lumryz Dosage and Administration


Take ≥2hrs after eating. Mix each dose with ~80mL of water. Initially 4.5g/night as a single dose. May increase by 1.5g/night at weekly intervals; usual range: 6–9g/night; max 9g/night. Switch from immediate-release sodium oxybate: use nearest equivalent dose in g/night. Allow 6hrs before becoming active after last dose. 


Not established.

Lumryz Contraindications


Concomitant sedative hypnotics or alcohol. Succinic semialdehyde dehydrogenase deficiency.

Lumryz Boxed Warnings

Boxed Warning

CNS depression. Abuse and misuse.

Lumryz Warnings/Precautions


Risk of CNS depression. Abuse potential (monitor). Respiratory dysfunction. Sleep-related breathing disorders (esp. in men, postmenopausal women not on HRT, obese, or narcolepsy patients). History of depression or suicidal ideation (monitor). Monitor for new or increased behavioral or psychiatric events. Consider sodium intake with heart failure, hypertension, renal insufficiency (see full labeling). Parasomnias. Hepatic impairment: not recommended. Drug abusers. Elderly. Labor & delivery. Pregnancy. Nursing mothers.


Only available through the Lumryz REMS Program. For more information call (877) 453-1029.

Lumryz Pharmacokinetics


  • Peak plasma concentrations after one 6g dose: 66 mcg/mL.
  • Time to peak plasma concentration after one 6g dose: 1.5 hours.


  • Apparent volume of distribution: 190–384 mL/kg.


  • Renal (<5%). Half-life: 0.5–1 hour. 

Lumryz Interactions


See Contraindications. CNS depression potentiated by concomitant other CNS depressants (eg, opioids, benzodiazepines, sedating antidepressants, antipsychotics, general anesthetics, muscle relaxants, sedating antiepileptics, illicit CNS depresants). May be potentiated by divalproex sodium.

Lumryz Adverse Reactions

Adverse Reactions

Nausea, dizziness, enuresis, headache, vomiting; CNS and respiratory depression, sleep-disordered breathing, sleepwalking, depressive symptoms, confusion, anxiety, other behavioral/psychiatric reactions.

Lumryz Clinical Trials

See Literature

Lumryz Note


Only available through the Lumryz REMS Program. For more information call (877) 453-1029.

Lumryz Patient Counseling

See Literature